Mark Lazenby, PhD, APRN, FAPOS, associate professor, Yale School of Nursing, discusses tools to measure distress in a patient with cancer.
Mark Lazenby, PhD, APRN, FAPOS, associate professor, Yale School of Nursing, discusses tools to measure distress in a patient with cancer.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPC
October 29th 2022A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.